These drugs work by limiting the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of axial spondyloarthritis.
England, Wales and Northern Ireland
The National Institute for Health and Care Excellence (NICE) approved the use of the JAK inhibitor upadacitinib, also known by the brand name, Rinvoq, on 30 September 2022 for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.
NICE then approved upadacitinib (Rinvoq) or treating active non-radiographic axial spondyloarthritis in adults on 01 February 2023.
NICE guidance covers England, Wales and Northern Ireland.
Upadacitinib (Rinvoq) has been approved by the Scottish Medicines Consortium for treating active non radiographic axial spondyloarthritis and active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Another JAK inhibitor called tofacitinib (Xeljanz) has also been accepted for use within NHS Scotland for treating active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.